Janus Henderson Group PLC Sells 321,789 Shares of Amgen Inc. $AMGN

Janus Henderson Group PLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 12.2% during the fourth quarter, HoldingsChannel reports. The firm owned 2,322,793 shares of the medical research company’s stock after selling 321,789 shares during the quarter. Janus Henderson Group PLC’s holdings in Amgen were worth $760,300,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC boosted its position in shares of Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC lifted its position in Amgen by 5.1% in the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after acquiring an additional 2,611 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wells Fargo & Company boosted their price objective on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. Mizuho boosted their price objective on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday. UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research report on Wednesday, April 8th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $354.42.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Amgen Trading Down 1.8%

Shares of NASDAQ:AMGN opened at $341.66 on Thursday. The company’s 50-day moving average price is $341.01 and its two-hundred day moving average price is $345.86. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The stock has a market capitalization of $184.40 billion, a PE ratio of 23.78, a price-to-earnings-growth ratio of 3.49 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the firm posted $4.90 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.